Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00084877 · ClinicalTrials.gov registry record · Phase 1
Irinotecan and 3-AP in Treating Patients With Metastatic or Unresectable Solid Tumors
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT00084877: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00084877 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 36 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00084877, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
This phase I trial is studying the side effects and best dose of irinotecan and 3-AP in treating patients with metastatic or unresectable solid tumors. Drugs used in chemotherapy such as irinotecan work in different ways to stop tumor cells from dividing so they stop growing or die. 3-AP may stop the growth of tumor cells by blocking the enzymes necessary for their growth and may help irinotecan kill more tumor cells by making them more sensitive to the drug.
Interventions
- OTHER laboratory biomarker analysis
- OTHER pharmacological study
- DRUG irinotecan hydrochloride
- DRUG triapine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2004-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00084877
The ClinicalTrials.gov registry entry for NCT00084877 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT00084877 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00084877 about?
NCT00084877 is a clinical study titled "Irinotecan and 3-AP in Treating Patients With Metastatic or Unresectable Solid Tumors". This phase I trial is studying the side effects and best dose of irinotecan and 3-AP in treating patients with metastatic or unresectable solid tumors. Drugs used in chemotherapy such as irinotecan work in different ways to stop tumor cells from dividing so they stop growing or die. 3-AP may stop th...
What is the current status of trial NCT00084877?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2004-03.
What interventions are being tested in trial NCT00084877?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), irinotecan hydrochloride (DRUG), triapine (DRUG).
Who is sponsoring clinical trial NCT00084877?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.